Jaguar Health Statement on Mytesi (crofelemer) April 2020 Price Adjustment and Commitment to Ensuring People Living with HIV Have Uninterrupted Access to Only FDA-Approved Non-Opioid, Plant-based, Anti-diarrheal Medicati

Jaguar Health Statement on Mytesi

(crofelemer) April 2020 Price Adjustment and Commitment to Ensuring People Living with HIV Have Uninterrupted Access to Only FDA-Approved

Non-Opioid, Plant-based, Anti-diarrheal Medication

The following provides important context regarding our recent

price adjustment for Mytesi (crofelemer), the first-in-class, non-opioid, plant-based drug product of Napo Pharmaceuticals,

Inc. (Napo), Jaguar's wholly owned subsidiary. Mytesi is approved by the U.S. Food and Drug Administration (FDA) for noninfectious

diarrhea in adults living with HIV/AIDS who are on antiretroviral therapy.

"Napo embodies the challenges faced by a small pharmaceutical

company with a novel product and pipeline and a long-standing commitment to sustainability in a reimbursement environment that

is rarely conducive to supporting innovation," said Lisa Conte, Jaguar Health President, CEO and Founder. "We look

forward to responding to the request for information from the U.S. House Committee on Oversight and Reform, and welcome the opportunity

to share our perspective on how we can continue to provide PLWH access to Mytesi and how to encourage a sustainable environment

for emerging pharmaceutical companies that support innovation in both drug development and commercialization."